During the past decade, ACSA CRS conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ACSA CRS" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 6 trials, followed by "McGill University Health Centre/Research Institute of the McGill University Health Centre" with 3 trials sponsored, "HIV Vaccine Trials Network" with 2 trials sponsored, "Janssen Vaccines & Prevention B.V." with 2 trials sponsored and "Golden Biotechnology Corporation" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ACSA CRS" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "Asociacion Civil Selva Amazonica" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator and "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "ACSA CRS" are "HIV Infections" (8 trials), "Intestinal Diseases, Parasitic" (2 trials), "Covid-19" (1 trials), "Dengue" (1 trials) and "Eye Abnormalities" (1 trials). Many other conditions were trialed in "ACSA CRS" in a lesser frequency.

Most popular intervention types in "ACSA CRS" are "Biological" (7 trials), "Drug" (5 trials), "Other" (5 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Observation" (2 trials), "AIDSVAX B/E vaccine" (1 trials), "Ad26.COV2.S" (1 trials) and "Ad26.Mos4.HIV" (1 trials). Other intervention names were less common.

The vast majority of trials in "ACSA CRS" are 14 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "ACSA CRS". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in ACSA CRS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ACSA CRS, 3 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".